


Zevaquenabant

Chemical Properties

CAS No. :	1998760-00-1
Formula:	C ₂₅ H ₂₁ ClF ₃ N ₅ O ₂ S
Molecular Weight:	547.98
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).
Targets(IC50)	Cannabinoid Receptor,Others,NO Synthase
In vitro	Zevaquenabant simultaneously inhibits CB1 receptors and iNOS in peripheral organs [1].
In vivo	Zevaquenabant (3 mg/kg; p.o.; for 28 days) significantly enhances renal morphology and function in diet-induced obese mice[1]. Using 6-week-old male C57Bl/6J mice as an animal model for diet-induced obesity[1], the administration of Zevaquenabant markedly improved kidney health and performance.

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8249 mL	9.1244 mL	18.2488 mL
5 mM	0.365 mL	1.8249 mL	3.6498 mL
10 mM	0.1825 mL	0.9124 mL	1.8249 mL
50 mM	0.0365 mL	0.1825 mL	0.365 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Udi S, et al. Dual inhibition of cannabinoid CB1 receptor and inducible NOS attenuates obesity-induced chronic kidney disease [published correction appears in Br J Pharmacol. 2021 Mar;178(5):1250]. Br J Pharmacol. 2020;177(1):110-127.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481